RE:RE:RE:RE:RE:RE:RE:Licensing agreement?The PGX demo plant should be at 10L. Scaling up 5 to 10 X takes it to 50 to 100 L which is adequate for commercial production.
It's been said that scaling up was to allow Ceapro to go alone with their PGX YBG immune booster and in parallel the capacity could be used for any commercial PGX alginate or YBG substrates to be loaded with bioactives. So yes, scaling up takes them to commercial production if a licenced deal is reached, but the current demo plant does allow initial NCC to be produced with customer desired bioactives for product development. Risk averse Ceapro is scaling up to commercial production capacity for an immune booster based on a demo unit. Potential customers don't have much risk here at this stage.